It May Soon Be Possible to Screen for Ovarian Cancer

Zepatier Offers New Option for Patients with Chronic Hepatitis C
February 3, 2016
Low Percentage of Patients Screened for Hepatitis C at Community Health Centers
February 4, 2016
Show all

It May Soon Be Possible to Screen for Ovarian Cancer

A new blood test is under development that could detect ovarian cancer.

There is no reliable way to detect ovarian cancer, which may explain why most women who are diagnosed already have advanced disease. But this test may change that

Ovarian cancer is the fourth-leading cause of cancer deaths among women in the U.S., but unlike with breast cancer, there is no mammogram equivalent that can seek out early lesions before they become difficult to treat.

A blood test, called CA125, can pick up signs of tumors in the ovaries, but it’s not very specific or sensitive for these growths. CA125 levels can rise not just because of ovarian tumors but during menstruation and pregnancy as well. That may explain why the test only picks up 60% to 65% of cancers.

But scientists report in The Lancet that there may be a way to pick up early ovarian tumors and potentially save lives. Ian Jacobs, president and vice chancellor of the University of New South Wales, and his colleagues conducted the largest study to date on an innovative way to use CA125 testing to screen women for ovarian cancer. Jacobs created an algorithm that incorporated several CA125 readings over time, with a woman’s age, to tighten the blood test’s connection to ovarian cancer risk.

A single CA125 reading may not be helpful, he notes, since women may have varying baseline levels of the substance. Even if the cutoff for possible ovarian cancer is any result above 35microns/ml, for example, some women may simply have higher circulating CA125 and not have cancer. But if several readings over a few years show that the CA125 is increasing rapidly, that’s a signal that a tumor could be growing.

Jacobs randomly assigned more than 202,000 women to get either no screening, only ultrasound screening or a combination of CA125 using the algorithm every year for an average of 11 years. He wanted to test whether the CA125 test along with its algorithm could be an effective way to screen women for ovarian cancer, so after a follow up of about 14 years, he compared these three groups of women on whether they had developed ovarian cancer or not, and whether they had died from the disease.

Overall, the women who received the CA125 screening with the algorithm lowered their risk of dying from ovarian cancer by 15%, while those who relied only on ultrasound reduced their risk of dying by 11%. That wasn’t a statistically significant difference, but when the researchers adjusted those results for the effect from women who might have already had ovarian cancer before starting the study but didn’t know it, the reduction was even more dramatic for women screened with CA125: 28%.

“The exciting thing about this paper is that it’s the first evidence that suggests if you catch the cancer early enough, perhaps it can save lives,” says Jacobs.

Dr. Karen Lu, chair of gynecologic oncology and reproductive medicine at University of Texas MD Anderson Cancer, welcomes the results. “I’m tired of seeing women come to me with late-stage disease,” says Lu, who was not involved in the study but has conducted trials on using annual CA125 and other markers to screen for ovarian cancer. “It’s devastating. About 70% of the time, if not more, we see women come to us with very advanced stage disease. What this study clearly shows is that with the CA125 test and the algorithm, we are detecting cancers at an earlier stage. And we’re seeing fewer deaths in women who get the screening. We’ve never had a study before that showed that early detection [of ovarian cancer] can save lives.”

 

Read Full Article: It May Soon Be Possible to Screen for Ovarian Cancer | TIME

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.